Genmab A/S (NASDAQ:GMAB) Upgraded at TD Cowen

TD Cowen upgraded shares of Genmab A/S (NASDAQ:GMAB) from a hold rating to a buy rating in a report released on Wednesday, MarketBeat.com reports. TD Cowen currently has $43.00 price target on the stock, up from their prior price target of $32.00.

GMAB has been the subject of several other reports. Wolfe Research began coverage on Genmab A/S in a research note on Friday, March 27th. They set an “outperform” rating and a $32.00 price objective for the company. HC Wainwright lifted their target price on Genmab A/S from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Truist Financial initiated coverage on Genmab A/S in a research note on Wednesday, May 27th. They set a “buy” rating and a $40.00 price target for the company. Finally, The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $39.28.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $28.87 on Wednesday. Genmab A/S has a one year low of $21.00 and a one year high of $35.43. The stock has a market capitalization of $18.00 billion, a price-to-earnings ratio of 21.87, a PEG ratio of 1.85 and a beta of 0.84. The company has a 50-day simple moving average of $26.82 and a 200-day simple moving average of $28.32. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC raised its stake in shares of Genmab A/S by 291.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after buying an additional 616 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in Genmab A/S during the first quarter worth $34,000. NewEdge Advisors LLC grew its holdings in Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after acquiring an additional 1,143 shares during the period. Finally, Brown Brothers Harriman & Co. grew its holdings in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after acquiring an additional 780 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.